참고문헌
- 과학기술부. 과학기술 연구 활동 조사보고. 2001
- 권명중, 유정식, 이태정, 양준모. 산업 수명주기론을 응용한 연구개발투자의 경제적 평가:의료기기산업을 중심으로. 중소기업연구. 제 27호 제2권. 2005
- 김종권. 제약 산업 R&D투자 효과분석. 보건경제연구. 2003; 9(1)47:-58
- 박용규. 통계시리즈 (IX): 로지스틱 회귀분석. 가정의학회지 제 22권 제 7호.2001
- 유승훈, 양창영. 공공보건지출과 경제적 성과에 대한 다국가 분석. 재정논집. 제 19집 제 1호. 2004
- 이공래. 지역기술혁신체제에서의 공공연구기관의 역할과 발전 방향. 과학기술정책연구원 정책자료. 2004
- 이태진, 김재용, 성주헌. 장애보정손실년수를 이용한 우리나라 주요 심혈관계 질환의 질병부담 추정. 보건경제연구. 2002; 8(1): 91-100
- 이훈영. 이훈영교수의 마케팅 조사론. 도서출판 청람. 2005
- 정광모, 최용석. 로지스틱 회귀와 응용-SAS 예제와 해석 중심. 자유 아카데미. 2003
- 정기택 외. 진료비 청구명세서 내용 및 작성. 청구방법 개선의 타당도 제고 방안 연구. 건강보험심사평가원. 경희대학교 의료산업연구원. 2003
- 정영호, 고숙자. 5 대 사망원인 질병의 사회. 경제적 비용추계. 재정논집. 2004; 18(2): 77-104
- 정영호. 보건산업의 연구개발(R&D)파급 분석. 보건경제연구. 2002; 8(1):107-134
- 한국보건산업진흥원. 보건산업 실태조사 및 산업연관 분석. 2003
- 한국보건산업진흥원. 보건산업 백서. 2004
- Bahk, Byong-Hyong and Micheal Gort. Decomposing learning by doing in new plants. Journal of Political Economy. 1993; 101: 561-583 https://doi.org/10.1086/261888
- Barbara HM, 이은현 등 옮김. 보건통계분석. 군자출판사. 2002
- Berger, ML, Murray, JF, Xu, J, Pauly, M. Alternative Valuations of work loss and productivity. American College of Occupational and Environmental Medicine. 2001;43:18-24 https://doi.org/10.1097/00043764-200101000-00005
- Berndt, Ernst, Margaret K. Kyle, and Davina Ling. The long shadow of patent expiration: Do Rx to OTC switches provide an afterlife? Scanner data and price indexes, ed. 2003
- Boston Consulting Group. The contribution of pharmaceutical companies: What's at stake for america, executive summary. Unpublished report, Boston Consulting Group Inc. 1993
- Culter, David, and Mark McClellan. Is technological change in medicine worth it? Health Affairs. 2001; 20(5): pp.11-29 https://doi.org/10.1377/hlthaff.20.5.11
- Fagerberg, J. A technology gap approach to why growth rates differ. Research Policy. 1987; 16
- Freeman, C. and Soete, L. The economics of industrial innovation. Cambridge: The MIT Press. 1997
- Griliches, Z and Lichtenberg F. 'R&D and productivity at the industry level: Is there still a relationship?,' in R&D, patent and productivity. Zvi Griliches, ed. Chicago: Univ. of Chicago Press. 1984
- Hulten, Charles R. Growth accounting when technical changes embodied in capital. The American Economic Review. 1992; Vol. 82, No. 4. pp. 964-980
- IMS Health: :MIADS, MAT, June 2004
- Jones, C I. R&D based models of economic growth. Journal of Political Economy. 1995;103(4): 759-786 https://doi.org/10.1086/262002
- Lichtenberg, F and Siegel. The impact of R&D investment on productivity: New evidence using linked R&D-LRD data. Economic Inquiry. 1991;29: 203-28 https://doi.org/10.1111/j.1465-7295.1991.tb01267.x
- Lichtenberg, F. Do (more and better) drugs keep people out of hospitals? the American Economic Review; 1996; 86(2):384-388
- Lichtenberg, F. Pharmaceutical innovation, mortality reduction and economic growth. NBER. 1998; working paper 6569
- Lichtenberg, F. The allocation of publicly-funded biomedical research. NBER. 1998; working paper no. 6601
- Lichtenberg, F. The benefits and costs of newer drugs: evidence from the 1996 medical expenditure panel survey. NBER. 2001. working paper no. 8147
- Lichtenberg, F. Sources of U.S. longevity increase, 1960-1997. NBER. 2002; working paper no. 8755
- Lichtenberg, F. The effect of changes on drug utilization on labor supply and per capita output. National Bureau of Economic Research. 2002; working paper No. 9139
- Lichtenberg, F. Pharmaceutical embodied technical progress, longevity and quality of life: Drug as 'Equipment for your health'. National Bureau of Economic Research working paper no. 9351. 2002
- Lichtenberg, F. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. NBER 2003. working paper 9754
- Lichtenberg, F. R The expanding pharmaceutical arsenal in the war on cancer. NBER. 2004a. working paper 10328
- Lichtenberg, F. The effect of drug vintage on survival: micro evidence from Puerto Rico's Medicaid program. NBER. 2004b; working paper no. 10884
- Mosby's Drug Consult CD-ROM
- Murphy, Kevin, and Robert Topel. The economic value of medical research. The value of medical research, ed. Chicago: Univ. of Chicago Press. 2002
- New York Times. Cholesterol pill linked to lower hospital bills. 1995; 27 March: p. A11
- Sakellaris P and Dan W. The production-side approach to estimating embodied technological change. Electronic Working Papers. University of Maryland. Department of Economics. 2000
- Romer, Paul. Endogenous technological change. Journal of Political Economy. 1990;98:S71-S102 https://doi.org/10.1086/261725
- Solow, RM. A contribution to the theory of economic growth. Quarterly Journal of Economics. 1956; 70: 65-94 https://doi.org/10.2307/1884513
- Solow, RM. Technical progress, capital formation and economic growth. The American Economic Review. 1962; Vol. 52, No. 2: pp. 76-86
- FDA New Drug Approval Reports(http://www.dfa.gov/cder/rdmt/defaulth.tml)
- http://100.naver.com/100.php?id=83267
- http://ezdrug.kfda.go.kr
- http://www.phrma.org/publications/publications//2005-03-17.1145.pdf
- http://www.phrma.org/publications/publications//2005-03-17.1145.pdf
- KMLE(http://drug.kmle.co.kr)
- National Science Foundation (http://www.nsf.gov/statistics/infbrief/nsf03306/)
- National Science Foundation (http://www.nsf.gov/statistics/infbrief/nsf03306/)
- 일간보사 의학신문 (http://www.bosa.co.kr/news_board/view.asp?news_pk=78029)
- 인구주요통계. 통계청 2005(http://kosis.nso.go.kr/cgi-bin/sws_999.cgi)
- 통계청(http://www.nso.go.kr/newnso/standard/disease/dis_search.html)
- 한국표준질병 . 사인분류 제 4차 개정판 (Korean Classification of Disease or KCD)
피인용 문헌
- Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature vol.9, pp.6, 2009, https://doi.org/10.1586/erp.09.64